Multicomponent Analysis of phYsical Frailty BiomarkErs: Focus on Mitochondrial Health - MAYBE
NCT ID: NCT05938205
Last Updated: 2023-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
111 participants
INTERVENTIONAL
2019-03-01
2022-07-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sarcopenia Physical Activity and Metabolomic
NCT05199207
Multidisciplinary Combined Exercise and Nutrition Intervention for Sarcopenia
NCT04948736
Effects of Resistance and Endurance Training on Synthesis of Individual Muscle Proteins in Young and Older Adults
NCT01489930
Influence of Sarcopenia on the Course of the Diseases
NCT06829290
Biomarkers of Sarcopenia and Frailty in Geriatric Patients
NCT05795556
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Anthropometric and body composition In the morning, in a fasted state, body mass will be taken with an electronic scale (Tanita electronic scale BWB-800 MA) and stature will be measured with a Harpenden stadiometer (Holtain Ltd., Crymych, Pembs. UK); BMI will be calculated as weight (kg)/height (m)2. Thereafter, total and regional body composition will be evaluated by means of dual-energy X-ray absorptiometry (DXA) using a total body scanner (QDR Horizon W, Hologic, MA, USA; fan-bean technology, software for Windows XP version 12.4.2) according to the manufacturer's procedures. Furthermore, the ALMI will be calculated as the sum of lean mass of arms and legs divided by height squared.
Physical performance On the same day, the SPPB test will be used to assess functional performance of the lower extremities. Each participant will performed: 4 m at usual customary gait speed, a five repeated chair-stands test and three standing balance tests (side by side, semi-tandem and tandem).
A digital dynamometer (CAMRY, Digital Hand Dynamometer model: EH101) will be used to assess HGS and all measurements were conducted by the same operator. Before starting, participants will observe a demonstration of the test procedure and engage in two practice attempts.
Knee muscle strength measurements and analysis An isokinetic dynamometer (CMSi Cybex Humac Norm Dynamometer, Lumex, Ronkokoma, NY, USA) will be used to assess the isokinetic strength of knee flexors and extensors muscles.
Maximal isokinetic knee extension-flexion tests will be performed in a randomised sequence at 60, 90, 150, 180 and 210°ˑs-1. Trials will consist in three knee extension-flexion movements with 60 s-recovery. The maximal strength of knee extensors muscle will be calculated with the Hill's hyperbolic function. The isokinetic knee extension-flexion power will be calculated as the product between strength and velocity. Finally, for knee extensors, maximal muscle power expressed in Watt, will be calculated from the power-velocity curve.
1-RM assessment Before starting training intervention, participants will perform three sessions of familiarization with the resistance isotonic machines. High intensity strength exercise (Exe-H) protocol: All the participants will performed a supervised progressive resistance training protocol, three times per week, 1 hour per session. Each participant will performed the same strength training protocol, starting with 3 sets of 8-10 repetitions at 70% of 1-RM (month 1), with a progressive increase of intensity at 75% of 1-RM (month 2 and month 3), and 80% 1-RM that will be maintained for the rest period of intervention. The compliance will be define as the number of exercise sessions expressed in % of the target value. Each participant will must reach a compliance above the 70% to be included in the final analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exe-H + placebo
high intensity physical exercise combined with placebo
Placebo
Nutritional Placebo
Exe-H
high intensity physical exercise
Exe-H + AA-1
high intensity physical exercise combined with low dose of aminoacids
AA-1
low dose aminoacids
Exe-H
high intensity physical exercise
Exe-H + AA-2
high intensity physical exercise combined with high dose of aminoacids
AA-2
high dose aminoacids
Exe-H
high intensity physical exercise
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AA-1
low dose aminoacids
AA-2
high dose aminoacids
Placebo
Nutritional Placebo
Exe-H
high intensity physical exercise
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The presence of sarcopenic obesity was considered when the following two conditions were satisfied: Fat mass \> 34.8% and FFM \<90% of subject's ideal FFM.
* Resident in Verona (Italy)
* Stable weight in the previous 2 months
* Previously sedentary (less than one hour of exercise per week in the last 6 months)
* Signing of the informed consent for participation in the study
Exclusion Criteria
* Malignant or unstable arrhythmias
* Heart failure NYHA class \> II
* Severe respiratory failure
* Severe heart valve disease (i.e severe aortic stenosis or insufficiency)
* Abdominal and/or thoracic aneurysm
* Recent intracerebral or subdural haemorrhage
* Poorly controlled arterial hypertension
* Presence of pacemakers or metal prostheses
* Severe chronic renal failure
* Symptomatic musculoskeletal pathology
* Symptomatic disc herniation, arthrosis, acute joint, tendon and ligamentous injuries, hip and/or knee prostheses recently placed (\<6 months) or with joint instability, symptomatic or large inguinal or abdominal hernia
* Acute retinal detachment or bleeding
* Recent eye surgery (laser, cataract, retinal surgery, glaucoma surgery)
* History of malignant cancer within the previous 5 years
* Diagnosis of dementia
* Eating disorders
60 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Università degli Studi di Brescia
OTHER
Azienda Ospedaliera di Padova
OTHER
University of Milan
OTHER
Azienda Ospedaliera Universitaria Integrata Verona
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elena Zoico, PhD
Role: STUDY_DIRECTOR
Universita di Verona
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AOUI Verona
Verona, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Healthy Aging Center Verona web site
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1956CESC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.